Invion Ltd. · ASX:IVX
Invion — Shareholder Meeting (November 2016)
13 slides from Invion's shareholder meeting presentation, Nov 14, 2016
Slide 1: AGM Presentation November 2016
AGM Presentation November | 2016 For personal use only Invion Limited (ASX:IVX) Respiratory drug technologies targeting chronic airway disease
Slide 2: Respiratory drug assets at partnering stage
Respiratory drug assets at partnering stage For personal use only 01 02 Asset 1: Nadolol Asset 2: Zafirlukast • Beta adrenergic biased ligand targeted to reverse mucous • Leukotriene receptor antagonist (LTRA) that reduces metaplasia in the airway epithelium inflammation, constriction of the airways
Slide 3: Platform development position: summary
Platform development position: summary For personal use only Nadolol : capitalise on existing extensive research, Zafirlukast: capitalise on existing approved strong data package and current medical and successful oral therapy and medical and consumer consumer sentiment for better, more effective se
Slide 4: Nadolol
For personal use only Nadolol Target: treatment of signs and symptoms of chronic airway disease via reduction of mucous production and airway healing
Slide 5: Nadolol directly targets pathway necessary for mucous metaplasia
Nadolol directly targets pathway necessary for mucous metaplasia For personal use only External research shows The necessary and sufficient role of the beta arrestin pathway in the development of mucous metaplasia and the chronic bronchitis phenotype (Bond, Dickey) 01 The role of biased ligand activ
Slide 6: Invion research has demonstrated
Invion research has demonstrated For personal use only Nadolol reduces the MUC5AC signal in a clinically relevant and statistically significant way compared with placebo Inhaled formulation shows no dose Nadolol can be safely administered to patients limiting adverse effects during 4-5 days with ast
Slide 7: Partnering opportunity: near term value inflection
Partnering opportunity: near term value inflection For personal use only Current asset status FY 2016 – FY 2018 By mid calendar year 2019 Oral Nadolol 2 x POC studies in mild asthma (Hanania); Completed P2 in mild asthma (data 2H16) P2 (proof of concept) study: reduction of signs Proof of concept da
Slide 8: Zafirlukast
For personal use only Zafirlukast Target: inhaled non-steroidal anti-inflammatory treatment for asthma with delivery method that reduces/ eliminates systemic side effects
Slide 9: Inhaled reformulation of a successful oral therapeutic for asthma
Inhaled reformulation of a successful oral therapeutic for asthma For personal use only By enabling reduced ICS dose “steroid sparing” in steroid-dependent asthma Leukotriene-receptor antagonist (LTRA) or By addition to low dose ICS treatment “anti-leukotriene” that reduces inflammation, rather than
Slide 10: Inhaled zafirlukast to address major unmet medical need
Inhaled zafirlukast to address major unmet medical need For personal use only Current therapies linked to depression and psychotic episodes in children 01 Emerging consumer awareness and activism for better education and more detailed 02 explanation of side effects FDA Black box warnings exist 03 In
Slide 11: Framework for reformulation of zafirlukast
Framework for reformulation of zafirlukast For personal use only Agreement reached Toxicology and bioanalytical IND submission and Assay (GLP) to support clinical program with FDA on: 4 weeks’ dosing • Chemistry manufacturing • 2 species for 28 days: • Phase 1: single rising dose and controls (GMP)
Slide 12: Finance position
Finance position For personal use only Cash reserves of $0.664 million at the end of September 2016 Operating cash outflows have been reduced reflecting lower capital-intensive activity following the completion of major R&D program milestones Cash outflows during the September quarter were $0.
Slide 13: Contact
For personal use only Dr Greg Collier Managing Director and CEO Invion Limited P: +61 7 3295 0500 E: greg.collier@inviongroup.com W: www.inviongroup.com DisclaimerThe information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive